Glucose, Obesity, Metabolic Syndrome, and Diabetes Relevance to Incidence of Heart Failure

被引:138
作者
Horwich, Tamara B. [1 ]
Fonarow, Gregg C. [1 ]
机构
[1] Univ Calif Los Angeles, Ahmanson UCLA Cardiomyopathy Ctr, Med Ctr, Los Angeles, CA 90095 USA
关键词
glucose; obesity; heart failure; metabolic syndrome; diabetes; IMPAIRED FASTING GLUCOSE; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; RISK-FACTORS; REVERSE EPIDEMIOLOGY; ATHEROSCLEROSIS RISK; SCIENTIFIC STATEMENT; WEIGHT-LOSS; FOLLOW-UP;
D O I
10.1016/j.jacc.2009.07.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure (HF) is common, results in poor clinical outcomes, and is associated with large health care costs. The incidence of HF continues to rise, with approximately 670,000 new cases per year and a 20% lifetime risk of HF for persons 40 years and older in the U. S. Risk factors for HF have been identified, and thus preventative strategies should have a positive effect on disease burden, morbidity, and mortality. Although coronary artery disease and hypertension have traditionally been considered among the most important modifiable risk factors for the development of HF, recent studies have highlighted the importance of increasingly prevalent metabolic risk factors: glucose, diabetes, obesity, and the metabolic syndrome. This report will present evidence for the link between glucose, diabetes, obesity, metabolic syndrome, and incident HF. Furthermore, we will discuss how risk factor modification and other preventive therapies may help curb the rising incidence of HF. (J Am Coll Cardiol 2010; 55: 283-93) (C) 2010 by the American College of Cardiology Foundation
引用
收藏
页码:283 / 293
页数:11
相关论文
共 72 条
[11]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[12]   Metabolic syndrome and the risk of cardiovascular disease in older adults [J].
Butler, J ;
Rodondi, N ;
Zhu, YW ;
Figaro, K ;
Fazio, S ;
Vaughan, DE ;
Satterfield, S ;
Newman, AB ;
Goodpaster, B ;
Bauer, DC ;
Holvoet, P ;
Harris, TB ;
de Rekeneire, N ;
Rubin, S ;
Ding, JZ ;
Kritchevsky, SB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) :1595-1602
[13]   Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose - Results of the Diabetes Reduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial [J].
Dagenais, G. R. ;
Gerstein, H. C. ;
Holman, R. ;
Budaj, A. ;
Escalante, A. ;
Hedner, T. ;
Keltai, M. ;
Lonn, E. ;
McFarlane, S. ;
McQueen, M. ;
Teo, K. ;
Sheridan, P. ;
Bosch, J. ;
Pogue, J. ;
Yusuf, S. .
DIABETES CARE, 2008, 31 (05) :1007-1014
[14]   A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure [J].
Dargie, Henry J. ;
Hildebrandt, Per R. ;
Riegger, Guenter A. J. ;
McMurray, John J. V. ;
McMorn, Stephen O. ;
Roberts, Jeremy N. ;
Zambanini, Andrew ;
Wilding, John P. H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (16) :1696-1704
[15]   Megatrials in type 2 diabetes. From excitement to frustration? [J].
Del Prato, S. .
DIABETOLOGIA, 2009, 52 (07) :1219-1226
[16]   Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes - A retrospective cohort study [J].
Delea, TE ;
Edelsberg, JS ;
Hagiwara, M ;
Oster, G ;
Phillips, LS .
DIABETES CARE, 2003, 26 (11) :2983-2989
[17]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[18]   Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes [J].
Duckworth, William ;
Abraira, Carlos ;
Moritz, Thomas ;
Reda, Domenic ;
Emanuele, Nicholas ;
Reaven, Peter D. ;
Zieve, Franklin J. ;
Marks, Jennifer ;
Davis, Stephen N. ;
Hayward, Rodney ;
Warren, Stuart R. ;
Goldman, Steven ;
McCarren, Madeline ;
Vitek, Mary Ellen ;
Henderson, William G. ;
Huang, Grant D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) :129-U62
[19]   Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08) [J].
Erdmann, Erland ;
Charbonnel, Bernard ;
Wilcox, Robert G. ;
Skene, Allan M. ;
Massi-Benedetti, Massimo ;
Yates, John ;
Tan, Meng ;
Spanheimer, Robert ;
Standl, Eberhard ;
Dormandy, John A. .
DIABETES CARE, 2007, 30 (11) :2773-2778
[20]   An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure -: art. no. e1-91.e6 [J].
Eshaghian, S ;
Horwich, TB ;
Fonarow, GC .
AMERICAN HEART JOURNAL, 2006, 151 (01) :91.e1-91.e6